高盛-科伦博泰(6990.HK):业绩回顾:上半年sac-TMT销售额超预期,Lung06数据为核心关注点,新型ADC进入临床阶段-Kelun Biotech(6990.HK):Earnings Review:1H sac-TMT sales beat;Lung06 data as major focus with novel ADCs entering cli-20260818【8页】

发表回复

后才能评论